NeoGenomics wins Medicare coverage for RaDaR ST immunotherapy monitoring in advanced solid tumors
MolDX coverage now includes RaDaR ST for monitoring immune-checkpoint inhibitor response in late-stage solid tumors, expanding reimbursement while current ASCO guidance still treats ctDNA as complementary rather than a replacement for standard assessment.
